Colorectal cancer

Correlation between non-metastatic protein 23 expression and clinicopathological features of colorectal cancer in Asians

J. W. Fu and Chu, X. Q., Correlation between non-metastatic protein 23 expression and clinicopathological features of colorectal cancer in Asians, vol. 14, pp. 15597-15608, 2015.

The current meta-analysis was performed to investigate the association between non-metastatic protein 23 (NM23) expression, tumor pathology, and disease prognosis in colorectal cancer (CRC) among Asians. English and Chinese language-based electronic databases (e.g., PubMed, EBSCO, Ovid, Springerlink, Wiley, Web of Science, Wanfang databases, China National Knowledge Infrastructure, VIP databases) were searched using search terms to identify published studies relevant to NM23 and CRC with immunohistochemistry.

Mutation profile of KRAS and BRAF genes in patients with colorectal cancer: association with morphological and prognostic criteria

M. Samara, Kapatou, K., Ioannou, M., Kostopoulou, Ε., Papamichali, R., Papandreou, C., Athanasiadis, A., and Koukoulis, G., Mutation profile of KRAS and BRAF genes in patients with colorectal cancer: association with morphological and prognostic criteria, vol. 14, pp. 16793-16802, 2015.

KRAS and BRAF mutations are well-recognized molecular alterations during colorectal carcinogenesis, but there is little agreement on their effect on tumor characteristics. Therefore, we aimed to evaluate the distribution of the most common KRAS and BRAF mutations in Greek patients with colorectal cancer and their possible associations with clinical histopathological parameters. In this study, 322 and 188 colorectal carcinomas were used for the mutation analysis of KRAS (exon 2) and BRAF (exon 15) genes, respectively.

Diagnostic performance of microRNA-29a for colorectal cancer: a meta-analysis

M. L. Zhi, Liu, Z. J., Yi, X. Y., Zhang, L. J., and Bao, Y. X., Diagnostic performance of microRNA-29a for colorectal cancer: a meta-analysis, vol. 14, pp. 18018-18025, 2015.

Previous studies have revealed that the expression level of microRNA-29a (miR-29a) was remarkably different in colorectal cancer (CRC) patients and healthy controls, indicating that miR-29a can be used as a diagnostic marker of CRC, but the results have been inconsistent. We conducted this meta-analysis to assess the diagnostic performance of blood-based miR-29a for CRC. We performed a systematic review of studies published over the past two decades to investigate the diagnostic performance of serum miR-29a for the diagnosis of CRC.

Subscribe to Colorectal cancer